Evidence map›Paper›PMID 28351177›Full record

ReviewExpert review of pharmacoeconomics & outcomes research2017

Direct and indirect cost of managing alzheimer's disease and related dementias in the United States.

Arijita Deb, James Douglas Thornton, Usha Sambamoorthi, Kim Innes

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of pharmacoeconomics & outcomes research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

110 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Observational
  11. Dissecting Alzheimer's disease heritability across populations.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

50 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Arijita Deba School of Pharmacy , Department of Pharmaceutical Systems and Policy, West Virginia University, Morgantown, USA.
James Douglas Thorntona School of Pharmacy , Department of Pharmaceutical Systems and Policy, West Virginia University, Morgantown, USA.
Usha Sambamoorthia School of Pharmacy , Department of Pharmaceutical Systems and Policy, West Virginia University, Morgantown, USA.
Kim Innesb School of Public Health, Department of Epidemiology , West Virginia University, Morgantown, USA.

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Anne Courtney DeVries · 2012 to 2026
$81.0M
Research Training Program in the Behavioral and Biomedical SciencesT32GM081741 · NIGMS · WEST VIRGINIA UNIVERSITY · PI BERREBI, ALBERT S, SIMPKINS, JAMES W. · 2008 to 2018
$2.1M
NIGMS NIH HHS T32 GM081741NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

introductionCare of individuals with Alzheimer's Disease and Related Dementias (ADRD) poses special challenges. As the disease progresses, individuals with ADRD require increasing levels of medical care, caregiver support, and long-term care which can lead to substantial economic burden. Areas covered: In this expert review, we synthesized findings from studies of costs of ADRD in the United States that were published between January 2006 and February 2017, highlighted major sources of variation in costs, identified knowledge gaps and briefly outlined directions for future research and implications for policy and program planning. Expert commentary: A consistent finding of all studies comparing individuals with and without ADRD is that the average medical, non-medical, and indirect costs of individuals with ADRD are higher than those without ADRD, despite the differences in the methods of identifying ADRD, duration of the study, payer type and settings of study population. The economic burden of ADRD may be underestimated because many components such as direct non-medical costs for home safety modifications and adult day care services and indirect costs due to the adverse impact of ADRD on caregivers' health and productivity are not included in cost estimates.

Indexed as

Cost of IllnessAlzheimer DiseaseCaregiversDementiaDisease ProgressionHealth Care CostsHumansLong-Term CareUnited Statesalzheimer’s diseaseDementiadirect costeconomic burdenindirect cost

Identifiers

PMID28351177
PMCPMC5494694

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.